Literature DB >> 19023912

Antimicrobial dosing strategies in critically ill patients with acute kidney injury and high-dose continuous veno-venous hemofiltration.

Catherine S C Bouman1.   

Abstract

PURPOSE OF REVIEW: Delivery of appropriate antimicrobial therapy is a great challenge during continuous veno-venous hemofiltration (CVVH), particularly if the recommended higher doses are applied. The present contribution discusses the principles of drug dosing during CVVH and compares the various proposed dosing strategies. RECENT
FINDINGS: The basic principles underlying removal of antibiotics during CVVH and the published dosing strategies are reviewed. The key factor to consider is the fractional CVVH clearance (FrCVVH). Critical illness and acute kidney injury, however, may dramatically affect the pharmacokinetic properties of a drug and thus FrCVVH. Five dosing strategies have been proposed on the basis of either available references, total creatinine clearance, the reduction in total body clearance, the maintenance dose multiplication factor, or therapeutic drug monitoring. Dose predictions according to the various strategies show reasonable approximations for some but not all antibiotics.
SUMMARY: The delivery of appropriate antimicrobial therapy during CVVH leaves us with uncertainty and presents a great challenge. To ensure efficacy and prevent toxicity, therapeutic drug monitoring is highly recommended. In the absence of therapeutic drug monitoring, adequate concentrations can only be inferred from clinical response. For nontoxic antibiotics overdosing is preferred to underdosing because the danger of underdosing is far greater than that of overdosing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19023912     DOI: 10.1097/mcc.0b013e32830f937c

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  8 in total

1.  How to explain and exploit the beneficial effects of high-volume hemofiltration on hemodynamics and strong ion gap.

Authors:  H M Oudemans-van Straaten; P W Elbers
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

Review 2.  Peritoneal dialysis for acute kidney injury.

Authors:  Brett Cullis; Mohamed Abdelraheem; Georgi Abrahams; Andre Balbi; Dinna N Cruz; Yaacov Frishberg; Vera Koch; Mignon McCulloch; Alp Numanoglu; Peter Nourse; Roberto Pecoits-Filho; Daniela Ponce; Bradley Warady; Karen Yeates; Fredric O Finkelstein
Journal:  Perit Dial Int       Date:  2014 Jul-Aug       Impact factor: 1.756

Review 3.  Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction.

Authors:  Frieder Keller; Bernd Schröppel; Ulla Ludwig
Journal:  World J Nephrol       Date:  2015-07-06

4.  The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children.

Authors:  Enno D Wildschut; Annewil van Saet; Pavla Pokorna; Maurice J Ahsman; John N Van den Anker; Dick Tibboel
Journal:  Pediatr Clin North Am       Date:  2012-08-29       Impact factor: 3.278

Review 5.  Pro/con debate: continuous versus intermittent dialysis for acute kidney injury: a never-ending story yet approaching the finish?

Authors:  Raymond Vanholder; Wim Van Biesen; Eric Hoste; Norbert Lameire
Journal:  Crit Care       Date:  2011-01-28       Impact factor: 9.097

Review 6.  Treatment with echinocandins during continuous renal replacement therapy.

Authors:  Francisco González de Molina; Maria de Los Ángeles Martínez-Alberici; Ricard Ferrer
Journal:  Crit Care       Date:  2014-03-28       Impact factor: 9.097

Review 7.  Optimizing antimicrobial therapy in critically ill patients.

Authors:  Virginie Vitrat; Serge Hautefeuille; Cécile Janssen; David Bougon; Michel Sirodot; Leonardo Pagani
Journal:  Infect Drug Resist       Date:  2014-10-20       Impact factor: 4.003

8.  Leukocyte capture and modulation of cell-mediated immunity during human sepsis: an ex vivo study.

Authors:  Thomas Rimmelé; Ata Murat Kaynar; Joseph N McLaughlin; Jeffery V Bishop; Morgan V Fedorchak; Anan Chuasuwan; Zhiyong Peng; Kai Singbartl; Daniel R Frederick; Lin Zhu; Melinda Carter; William J Federspiel; Adriana Zeevi; John A Kellum
Journal:  Crit Care       Date:  2013-03-26       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.